Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene.
In conclusion, our study demonstrates that targeting FXR and improving its function might be a promising strategy for CRC treatment.
PMID: 33164339 [PubMed - as supplied by publisher]
Source: J Cell Mol Med - Category: Molecular Biology Authors: Li S, Xu Z, Guo J, Zheng J, Sun X, Yu J Tags: J Cell Mol Med Source Type: research
More News: Bile | Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Genetics | Molecular Biology | Study